Jeffrey A. Sosman

5 ta ish

Cornell University

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

   F. Stephen Hodi, Steven O’Day, David F. McDermott +26

   MaqolaOAOchiq kirish201010 iqtibos

   ABIABI:AkademIndex/2026.other.121325

2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

   Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.132162

3. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

4. Molecular Pathways: Targeting <i>NRAS</i> in Melanoma and Acute Myelogenous Leukemia

   Douglas B. Johnson, Keiran S.M. Smalley, Jeffrey A. Sosman

   Sharh maqola20142 iqtibos

   ABIABI:AkademIndex/2026.other.574571

5. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

   Robert J. Motzer, Bernard Escudier, Ray McDermott +24

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.679071